Event Calendar
Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery
PETACH TIKVA,
The presentation will be delivered by Dr.
The ASEPSIS score is a validated, objective clinical scoring system used to assess the severity of surgical wound infections. It integrates parameters such as wound appearance, antibiotic use, drainage of pus, isolation of pathogenic bacteria, and length of hospital stay. As previously reported in the SHIELD II topline results, treatment with D-PLEX100 together with the standard of care resulted in a 64% relative risk reduction (p=0.0103) in the proportion of patients with an ASEPSIS score greater than 20, the threshold indicative of clinically significant wound infection, compared to the standard of care alone.
"The ASEPSIS score outcomes demonstrate not only that D-PLEX₁₀₀ reduces surgical site infections (“SSI”) events by 60%, but also that those infections that ultimately breakthrough are less severe and less complicated," said Dikla Czaczkes Akselbrad, Chief Executive Officer of
| Title: | Evaluation of ASEPSIS Score as a Secondary Endpoint in the Phase 3 SHIELD II Trial of D-PLEX100 in Colorectal Surgery |
| Presenter: | , MD, |
| Session: | Scientific Session III |
| Date/Time: | | |
| Location: | , |
Analysis demonstrates D-PLEX₁₀₀ prolonged delivery mechanism ability to deliver continuous release of doxycycline for 30 days at the surgical incision site
PETACH TIKVA,
The abstract titled “Pharmacokinetics of local extended-release incisional doxycycline in patients undergoing abdominal colorectal surgery from the SHIELD II Phase 3 clinical trial,” was co-authored by Prof.
Key findings from the SHIELD II analysis:
- Sustained and controlled release profile: Detectable doxycycline concentrations were observed for up to 763 hours (approximately 32 days), with no burst, following local application of D-PLEX₁₀₀ during surgery.
Figure 1. Mean (+ standard deviation) plasma doxycycline concentration versus time profile
- Minimal systemic exposure: Plasma doxycycline concentrations remained below 100 ng/mL, indicating negligible systemic levels relative to oral doxycycline administration where Cmax levels are approximately 16 to 26 times higher (1,613.3 ng/mL for 100 mg1 and 2,600 ng/mL for 200 mg2 doses).
“These pharmacokinetic results further support the mechanism of D-PLEX₁₀₀, which is designed to deliver sustained and controlled antibiotic exposure for 30 days directly at the surgical incision site,” said Dikla Czaczkes Akselbrad, Chief Executive Officer of
ESCMID Global 2026 Presentation Details
| Poster Title: | Pharmacokinetics of Local Extended-Release Incisional Doxycycline in Patients undergoing Abdominal Colorectal Surgery from the SHIELD II Phase 3 Clinical Trial |
| Presenter: | , VP Clinical Affairs, |
| Lead Author: | Prof. |
| Poster Details: | #P2740 (Presented at: Poster Hall B3) |
| Session: | 05b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring |
| Date/Time: | | 12:00 – |